Does Medicare Cover GLP-1? 2026 Coverage Rules
Medicare coverage of GLP-1 medications has historically been limited and is gradually expanding. The headline answer: yes for diabetes, mostly no for weight loss alone, expanding for cardiovascular and sleep apnea indications. Details below.
Last updated May 1, 2026. CMS rules change; verify with your specific Part D plan.
Licensed providers · All 50 states · No insurance required
Quick Coverage Map (2026)
| Drug | Type 2 diabetes | Weight loss only | Other approved indication |
|---|---|---|---|
| Ozempic (semaglutide) | Generally covered (PA usually required) | Not typically covered | CV risk in T2D — may be covered |
| Wegovy (semaglutide) | N/A | Historically not covered | CV risk reduction — coverage expanding under recent CMS guidance |
| Rybelsus (oral semaglutide) | Generally covered | Not typically covered | — |
| Mounjaro (tirzepatide) | Generally covered | Not typically covered | — |
| Zepbound (tirzepatide) | N/A | Historically not covered | OSA in obesity — coverage expanding |
| Saxenda (liraglutide) | N/A | Historically not covered | — |
| Victoza (liraglutide) | Generally covered | Not typically covered | — |
| Trulicity (dulaglutide) | Generally covered | Not typically covered | CV risk in T2D — may be covered |
Why Medicare Historically Didn't Cover GLP-1 for Weight Loss
The Medicare Modernization Act of 2003 specifically excluded "drugs when used for the symptomatic treatment of weight loss or weight gain" from Part D coverage. This exclusion has been the main barrier. CMS has interpreted this strictly until recent indication expansions for cardiovascular and sleep apnea uses created openings for partial coverage.
The 2024–2026 Shift: CV and OSA Indications
Wegovy's FDA approval for cardiovascular risk reduction (based on SELECT trial) and Zepbound's approval for obstructive sleep apnea in obesity (SURMOUNT-OSA) gave CMS a basis to cover these drugs for those specific indications. Coverage rollout has been gradual and varies by plan.
- Wegovy for CV indication: Many Part D plans now cover with documentation of established cardiovascular disease.
- Zepbound for OSA: Coverage growing in 2026 with sleep study documentation.
- Weight management alone: Still typically excluded for most beneficiaries.
How to Get Coverage Approved
- Confirm the indication. Diabetes (most reliable), CV risk reduction (Wegovy), or OSA in obesity (Zepbound).
- Documentation. Your provider submits prior authorization with diagnosis codes, prior therapy attempts, and supporting labs/studies.
- Plan formulary. Check which GLP-1 is on your specific plan's preferred list — formularies differ.
- Step therapy. Many plans require trying older medications first (metformin, etc.).
If Denied: The Appeals Process
You have a formal right to appeal Medicare Part D denials. Steps:
- Redetermination request to your plan (within 60 days)
- Reconsideration by an Independent Review Entity if denied again
- Administrative Law Judge hearing for higher-value disputes
- Medicare Appeals Council
- Federal District Court
Strong appeals include: detailed prior therapy history, current weight-related comorbidities, documented medical necessity, and supporting trial citations. Your prescriber's office can prepare most documentation.
Licensed providers · All 50 states · No insurance required
If Coverage Is Denied: Practical Alternatives
- Compounded semaglutide via cash-pay telehealth — $199–399/month, the cheapest legal alternative for most patients
- Compounded tirzepatide via cash-pay telehealth — $299–499/month
- LillyDirect Zepbound vials — $349–550/month self-pay
- Manufacturer patient assistance programs — Note: many exclude Medicare beneficiaries due to anti-kickback statute; check current eligibility
- Older anti-obesity medications — phentermine, naltrexone/bupropion, etc. (smaller effect, lower cost, generally not covered by Medicare either for obesity-only indication)
Medicare Advantage Plans (Part C)
Medicare Advantage plans must cover at minimum what original Medicare covers. They can offer additional benefits (sometimes including weight-management programs). Coverage of GLP-1 still depends on the indication and the plan's drug formulary. Some MA plans now offer expanded weight-management coverage as a competitive benefit.
Medicaid Coverage
State Medicaid programs vary significantly. Some states cover Wegovy for obesity with prior authorization; others do not. Check your state's preferred drug list (PDL) and prior authorization criteria. Coverage has gradually expanded in 2025–2026.
What's Likely to Change
Legislation has been introduced in multiple Congresses to allow Medicare coverage of anti-obesity medications. Industry, patient advocacy, and CMS are actively engaged. Specific outcomes are uncertain; subscribe to our news page for monthly updates.
Frequently Asked Questions
Does Medicare cover Ozempic? +
Does Medicare cover Wegovy? +
Does Medicare cover Zepbound? +
Can I appeal a Medicare denial for GLP-1? +
What if Medicare won't cover my GLP-1? +
Related Reading
Sources
- Centers for Medicare & Medicaid Services (CMS) Part D drug coverage guidance. cms.gov
- Medicare.gov plan finder and formulary search.
- SELECT trial (Wegovy CV approval basis). NEJM 2023.
- SURMOUNT-OSA trial (Zepbound OSA approval basis). NEJM 2024.